Abbott/$ABT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Abbott
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
- Ticker
- $ABT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 115,000
- Headquarters
- Abbott Park, United States
- Website
- www.abbott.com
Abbott Metrics
BasicAdvanced
$190B
40.88
$2.69
0.54
$2.48
2.29%
Price and volume
Market cap
$190B
Beta
0.54
52-week high
$132.03
52-week low
$81.97
Average daily volume
9.5M
Dividend rate
$2.48
Financial strength
Current ratio
1.455
Quick ratio
0.825
Long term debt to equity
0.576
Total debt to equity
0.632
Dividend payout ratio (TTM)
91.98%
Interest coverage (TTM)
7.58%
Profitability
EBITDA (TTM)
11,954
Gross margin (TTM)
57.17%
Net profit margin (TTM)
9.75%
Operating margin (TTM)
15.65%
Effective tax rate (TTM)
28.36%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
4.90%
Return on equity (TTM)
9.14%
Valuation
Price to earnings (TTM)
40.876
Price to revenue (TTM)
3.958
Price to book
3.72
Price to tangible book (TTM)
-141.43
Price to free cash flow (TTM)
28.293
Free cash flow yield (TTM)
3.53%
Free cash flow per share (TTM)
3.885
Dividend yield (TTM)
2.26%
Forward dividend yield
2.29%
Growth
Revenue change (TTM)
10.00%
Earnings per share change (TTM)
-66.24%
3-year revenue growth (CAGR)
6.47%
10-year revenue growth (CAGR)
8.82%
3-year earnings per share growth (CAGR)
-2.87%
10-year earnings per share growth (CAGR)
11.37%
3-year dividend per share growth (CAGR)
7.30%
10-year dividend per share growth (CAGR)
9.25%
What the Analysts think about Abbott
Analyst ratings (Buy, Hold, Sell) for Abbott stock.
Analyst projections of the future price of Abbott stock.
Bulls say / Bears say
Third-quarter comparable sales grew 7% and adjusted EPS rose 9.2%, while adjusted gross margin expanded by 140 basis points. This shows earnings and margins improved alongside sales. (Abbott, The Motley Fool)
Cancer diagnostics grew 13.8% on a comparable basis in the third quarter, supported by Cologuard and precision oncology. That gives Abbott a growing diagnostics franchise beyond its established device businesses. (The Motley Fool)
Electrophysiology sales rose 15.5% on a comparable basis, with uptake of the Volt ablation catheter helping drive growth. FDA approval of the TactiFlex Duo catheter adds another product to Abbott’s launch pipeline. (Abbott)
Abbott cut its 2026 comparable sales growth outlook to about 6% from 6.5%–7.5%, citing softer-than-expected medical device demand. The lower outlook raises questions about near-term growth momentum. (Reuters)
Management expects diabetes growth to remain in the low-to-mid single digits over the next few quarters. Slower reimbursement expansion and international price competition are limiting growth in continuous glucose monitoring. (MDDI Online)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Abbott Financial Performance
Revenues and expenses
Abbott Earnings Performance
Company profitability
Upcoming events
Abbott News
AllArticlesVideos
Funds containing Abbott
AllEURUSDGBP
Fund name | Fund size | $ABT weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 2.93% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 2.90% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 2.90% |
SPDR MSCI World Health Care$WHEA | $708M | 2.16% |
SPDR MSCI World Health Care£HEAW | $708M | 2.16% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.